Withdrawals Slash CFDA’s 2015 Approval Numbers
This article was originally published in PharmAsia News
Executive Summary
China's milestone reforms to speed up new drug approvals debuted to wide applause but now the report cards are in and industry observers are less cheerful.
You may also be interested in...
2016 Review: Rapid Change Defines China Regulatory Environment
If you missed some of the many significant events in China’s policy and regulatory landscape in 2016, here is your opportunity to catch up on month-by-month developments.
Mission: Ongoing! China Looks To Align With FDA In Landmark IND Push
Issuing new guidance for INDs, doubling reviewers, adopting priority and accelerated reviews, and cutting a submission backlog are among the raft of measures the China FDA is quietly but assertively taking to accelerate new drug approvals and support innovation.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.